Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ocular surface changes induced by topical antiglaucoma monotherapy.

Barbara Cvenkel1, Alojz Ihan

  • 1Eye Clinic, Medical Center Ljubljana, Medical Faculty, Slovenia. barbara.cvenkel@kclj.si

Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory analysis of gut microbiota and its association with peripheral blood immune cell populations in canine myxomatous mitral valve disease.

BMC veterinary research·2026
Same author

Not all Group B <i>Streptococci</i> are alike: macrophage responses reveal inflammatory and immune-evasive strains.

Frontiers in cellular and infection microbiology·2026
Same author

Referral for glaucoma surgery and types of surgery in different European regions in 2025, the EURACCUR study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell Recovery.

Radiology and oncology·2026
Same author

Immune response in dogs with myxomatous mitral valve disease: insights into monocyte and lymphocyte subtypes and natural killer cells.

Journal of veterinary internal medicine·2026
Same author

CAR T therapy in adult DLBCL patients in Slovenia: Evaluation of predictive scores for outcomes and adverse events.

Human vaccines & immunotherapeutics·2026

Topical glaucoma monotherapy significantly increases subclinical inflammation, indicated by elevated HLA-DR expression on conjunctival epithelial cells. This occurs regardless of medication type, suggesting a common inflammatory pathway in glaucoma treatment.

Area of Science:

  • Ophthalmology
  • Immunology
  • Cell Biology

Background:

  • Glaucoma treatment often involves topical medications.
  • The ocular surface can be affected by these treatments.
  • Subclinical inflammation is a potential concern in long-term therapy.

Purpose of the Study:

  • To evaluate the expression of inflammatory markers, specifically HLA-DR, in patients using topical antiglaucoma monotherapy.
  • To assess subclinical inflammation in the conjunctival epithelium using impression cytology.

Main Methods:

  • Impression cytology specimens were collected from patients on no medication and those on monotherapy (latanoprost, betaxolol, timolol) for at least 3 months.
  • Patients had no clinical signs of ocular surface inflammation.
  • Flow cytometry was used to analyze HLA-DR expression on epithelial cells and T lymphocytes.

Related Experiment Videos

Main Results:

  • A significant increase in HLA-DR expression was observed on epithelial cells in all monotherapy groups compared to controls.
  • No significant correlation was found between treatment duration and inflammatory marker expression.
  • In the latanoprost group, increased HLA-DR expression was linked to shorter treatment duration.

Conclusions:

  • Single topical antiglaucoma medications, preserved with benzalkonium chloride, induce significant subclinical inflammation.
  • This inflammation is detectable as increased HLA-DR expression on conjunctival epithelial cells.
  • The findings highlight a potential inflammatory consequence of standard glaucoma monotherapy.